噻托溴铵联合孟鲁司特钠对慢性阻塞性肺疾病患者的临床疗效

The clinical efficacy of tiotropium bromide combined with montelukast sodium in patients with chronic obstructive pulmonary disease

目的分析噻托溴铵联合孟鲁司特钠治疗对慢性阻塞性肺疾病(COPD)患者的临床疗效及对第一秒用力呼气容积(FEV1)、总用力肺活量(FVC)、第一秒用力呼气量占总用力呼气量的比例(FEV1/FVC)水平的影响。方法选取2019年7月至2020年7月120例COPD患者,根据患者用药方案的不同分为A组、B组、C组,每组均40例;A组采用噻托溴铵联合孟鲁司特钠治疗,B组采用孟鲁司特钠治疗,C组采用噻托溴铵治疗。采用χ^(2)检验比较3组的临床疗效,采用t检验比较治疗前后3组肺功能指标FEV1、FVC、FEV1/FVC的变化。结果治疗后,A组治疗总有效率为95.0%,显著高于B组(75.0%)和C组(77.5%),差异具有统计学意义(χ^(2)值分别为6.275、5.165,P值均<0.05);治疗前A、B、C组肺功能FEV1、FVC、FEV1/FVC指标比较无明显差异,差异无统计学意义(F值分别为1.254、1.658、0.895,P值均>0.05);治疗后A组肺功能各指标均优于B组及C组,差异具有统计学意义(t值分别为2.794、3.885、4.590,3.821、4.031、4.323,P值均<0.05)。结论噻托溴铵联合孟鲁司特钠能够有效改善COPD患者的FEV、FVC、FEV1/FVC水平,从而提高临床治疗效果,值得推广。

Objective To analyze the clinical efficacy of tiotropium bromide combined with montelukast sodium treatment in patients with chronic obstructive pulmonary disease(COPD) and its influence on the levels of FEV, FVC and FEV1/FVC. Methods A total of 120 COPD patients, from July 2019 to July 2020 were selected and they were divided into groups A, B and C according to the different medication regimens, with 40 cases in each group. Group A was treated with tiotropium bromide combined with Montelukast sodium, group B was treated with Montelukast sodium, and group C was treated with tiotropium bromide. The χ2 test was used to compare the clinical efficacy of the 3 groups. The t test was used to compare the pulmonary function indexes the 3 groups before and after treatment, including forced expiratory volume in the first second(FEV1), forced vital capacity(FVC), and the change of forced expiratory volume in the first second accountedfor all expiratory volumes’ ratio(FEV1/FVC). Results After treatment, the total effective rate of group A was 95.0%, which was significantly higher than that in group B(75.0%) and group C(77.5%). The difference was statistically significant(χ^(2)= 6.275, 5.165;all P < 0.05). Before treatment, there was no significant in pulmonary function FEV1, FVC, FEV1/FVC indexes in groups A, B, and C, there were no statistical difference(F =1.254, 1.658, 0.895;all P > 0.05);after treatment, each index of pulmonary function in group A was better than group B and group C, there difference were statisticallly significant(t = 2.794, 3.885, 4.590, 3.821, 4.031, 4.323;all P < 0.05). Conclusion It is worthy for tiotropium bromide combined with Montelukast sodium to be promoted because it can effectively improve the FEV, FVC, FEV1/FVC levels of COPD patients, and the clinical treatment effect.